2',2',2'-tricholoethyl 4-bromobutyrate | 181704-15-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2',2',2'-tricholoethyl 4-bromobutyrate
• 英文别名: 2,2,2-trichloroethyl 4-bromobutyrate；4-Bromobutyric acid, 2,2,2-trichloroethyl ester；2,2,2-trichloroethyl 4-bromobutanoate
• CAS: 181704-15-4
• 化学式: C₆H₈BrCl₃O₂
• 分子量: 298.391
• InChiKey: BMKUEJKAWLEGCS-UHFFFAOYSA-N

物化性质

• 沸点：
  348.8±42.0 °C(Predicted)
• 密度：
  1.672±0.06 g/cm3(Predicted)
• 保留指数：
  1554

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2',2',2'-tricholoethyl 4-bromobutyrate 在 potassium carbonate 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.5h， 生成 allyl (11aS)-11-hydroxy-7-methoxy-5-oxo-8-[4-oxo-4-(2,2,2-trichloroethoxy)butoxy]-2,3,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate
  参考文献：
  名称：

  Unsymmetrical DNA Cross-Linking Agents:  Combination of the CBI and PBD Pharmacophores

  摘要：

  A set of 10 compounds, each combining the seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (seco-CBI) and pyrrolo[2,1-c][1,4]benzodiazepine (PBD) pharmacophores, was designed and prepared. These compounds were anticipated to cross-link between N3 of adenine and N2 of guanine in the minor groove of DNA. The compounds, which differ in the chain length separating the two alkylation subunits, and the configuration of the CBI portion, showed great variation in cellular toxicity (over 4 orders of magnitude in a cell line panel) with the most potent example exhibiting IC50S in the pM range. Cytotoxicity correlated with the ability of the compounds to cross-link naked DNA. Cross-linking was also observed in living cells, at much lower concentrations than for a related symmetrical PBD dimer. A thermal cleavage assay was used to assess sequence selectivity, demonstrating that the CBI portion controlled the alkylation sites, while the PBD substituent increased the overall efficiency of alkylation. Several compounds were tested for in vivo activity using a tumor growth delay assay against WiDr human colon carcinoma xenografts, with one compound (the most cytotoxic and most efficient cross-linker) showing a statistically significant increase in survival time following a single iv dose.

  DOI：

  10.1021/jm020526p
• 作为产物：
  描述：

  2,2,2-三氯乙醇 、 4-溴丁酰氯 以 二氯甲烷 为溶剂， 反应 4.0h， 以8.56 g的产率得到2',2',2'-tricholoethyl 4-bromobutyrate
  参考文献：
  名称：

  Unsymmetrical DNA Cross-Linking Agents:  Combination of the CBI and PBD Pharmacophores

  摘要：

  A set of 10 compounds, each combining the seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (seco-CBI) and pyrrolo[2,1-c][1,4]benzodiazepine (PBD) pharmacophores, was designed and prepared. These compounds were anticipated to cross-link between N3 of adenine and N2 of guanine in the minor groove of DNA. The compounds, which differ in the chain length separating the two alkylation subunits, and the configuration of the CBI portion, showed great variation in cellular toxicity (over 4 orders of magnitude in a cell line panel) with the most potent example exhibiting IC50S in the pM range. Cytotoxicity correlated with the ability of the compounds to cross-link naked DNA. Cross-linking was also observed in living cells, at much lower concentrations than for a related symmetrical PBD dimer. A thermal cleavage assay was used to assess sequence selectivity, demonstrating that the CBI portion controlled the alkylation sites, while the PBD substituent increased the overall efficiency of alkylation. Several compounds were tested for in vivo activity using a tumor growth delay assay against WiDr human colon carcinoma xenografts, with one compound (the most cytotoxic and most efficient cross-linker) showing a statistically significant increase in survival time following a single iv dose.

  DOI：

  10.1021/jm020526p

文献信息

• Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists
  作者：Bjarne Brudeli、Lise Román Moltzau、Kjetil Wessel Andressen、Kurt A. Krobert、Jo Klaveness、Finn Olav Levy

  DOI：10.1016/j.bmc.2010.10.011

  日期：2010.12

  agonists might have beneficial effects in the central nervous system (CNS) and therefore, 5-HT4 antagonists might cause CNS side effects. In this study, we have developed new amphoteric 5-HT4 antagonists. A series of cyclic indole amide derivatives possessing an oxazine ring and a piperidine alkane carboxylic acid side chain and the corresponding prodrug esters were synthesized and their binding to 5-HT4

  血清素（5-羟色胺，5-HT）是人体内重要的信号分子。5-HT 4血清素受体与G蛋白G s结合，在心脏，膀胱，胃肠道和肾上腺中起着重要的生理和病理生理作用。为了治疗这些器官中的疾病，已经开发了5-HT 4拮抗剂和激动剂。5-HT 4激动剂可能对中枢神经系统（CNS）具有有益作用，因此，5-HT 4拮抗剂可能引起CNS副作用。在这项研究中，我们开发了新的两性5-HT 4拮抗剂。合成了一系列具有恶嗪环和哌啶烷烃羧酸侧链的环状吲哚酰胺衍生物和相应的前药酯，并评价了它们与5-HT 4受体的结合和拮抗性能。另外，还测试了没有恶嗪环的吲哚酯和相应的吲哚酰胺衍生物。测试了一些合成配体的辛醇-水分布（Log  D Oct7.4）。5-HT 4的主要结构-亲和力特征测试的化合物是前药酯显示出比其相应的游离酸更高的亲和力，吲哚酯显示出比相应的酰胺更高的亲和力，并且在吲哚骨架中包含恶嗪环的配体显示出比不包含该环
• 5-HTX MODULATORS
  申请人：Klaveness Jo

  公开号：US20090029979A1

  公开（公告）日：2009-01-29

  This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT 2 or 5-HT 7 receptors, their preparation and use, compositions containing them, and methods of treatment using them.

  本发明涉及与中枢神经系统内或外的血清素受体结合的化合物，特别是与5-HT2或5-HT7受体结合的化合物，其制备和使用，包含它们的组合物以及使用它们的治疗方法。
• Modulators of Preripheral 5-Ht Receptors
  申请人：Klaveness Jo

  公开号：US20070254874A1

  公开（公告）日：2007-11-01

  Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to 5-HT4 receptors, despite the presence of an acidic moiety at the end of an optional chain. The entirely novel entities also exhibit good binding affinity to 5-HT4 receptors. All of the compounds of the invention have a common motif which includes a basic nitrogen moiety and an acidic moiety. The compounds of the invention, due at least in part to their high ionisation potential at physiological pH, have the unique properties of selectively for peripheral 5HT4 receptors over those of the CNS, good binding affinity, and selectively of 5HT4 receptors over other serotonin receptors.

  已经开发出了5-HT4受体的新型调节剂，其选择性针对的是外周受体而非中枢神经系统受体。其中包括已知调节剂的新型衍生物以及全新的实体。令人惊讶的是，已知调节剂的衍生物化合物尽管在可选链的末端存在酸性基团，但仍保持对5-HT4受体的高结合亲和力。全新的实体也表现出良好的5-HT4受体结合亲和力。发明中的所有化合物都具有一个共同的基团，其中包括一种碱性氮基团和一种酸性基团。该发明中的化合物，至少部分原因是由于它们在生理pH值下具有高离化电位，具有选择性地作用于外周5-HT4受体而非中枢神经系统受体，具有良好的结合亲和力，并且对5-HT4受体的选择性高于其他血清素受体。
• Modulators of peripheral 5-HT receptors
  申请人：Serodus AS

  公开号：US07834010B2

  公开（公告）日：2010-11-16

  The invention relates to modulators of peripheral 5-HT receptors, particularly 5-HT4 receptors, said modulators essentially selective for peripheral 5-HT receptors over receptors of the central nervous system. The invention allows for the treatment, amongst others, of gastrointestinal disorders, lower urinary tract disorders, and cardiovascular disorders without side effects related to CNS activity.

  本发明涉及外周5-HT受体的调节剂，特别是5-HT4受体，所述调节剂基本上选择性地作用于外周5-HT受体而不作用于中枢神经系统的受体。本发明允许治疗消化系统疾病、下尿路疾病和心血管疾病等疾病，而不会产生与中枢神经系统活动相关的副作用。
• [EN] MODULATORS OF PERIPHERAL 5-HT RECEPTORS<br/>[FR] MODULATEURS DE RECEPTEURS PERIPHERIQUES 5-HT
  申请人：BIO MEDISINSK INNOVASJON AS

  公开号：WO2005061483A3

  公开（公告）日：2005-10-27